BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-20 06:30 |
BioArctics globala licensavtal med Bristol Myers Squibb för pyroglutamat-amyloi…
|
Swedish | 206.2 KB | ||
| 2025-02-20 06:30 |
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamat…
|
English | 192.5 KB | ||
| 2025-02-18 08:00 |
Leqembi® sales reaches €200 million – first sales milestone achieved
|
English | 199.5 KB | ||
| 2025-02-18 08:00 |
Leqembi® når €200 miljoner i försäljning – första försäljningsmilstolpen uppnådd
|
Swedish | 207.2 KB | ||
| 2025-02-13 08:00 | Swedish | 1.5 MB | |||
| 2025-02-13 08:00 | English | 1.2 MB | |||
| 2025-02-07 04:35 |
Försäljningen av Leqembi® uppgick till 13,3 miljarder yen under det fjärde kvar…
|
Swedish | 196.9 KB | ||
| 2025-02-07 04:35 |
Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024
|
English | 169.7 KB | ||
| 2025-01-31 12:30 |
Update on regulatory review of lecanemab for treatment of early Alzheimer’s dis…
|
English | 182.2 KB | ||
| 2025-01-27 00:30 |
FDA godkänner intravenös underhållsbehandling med Leqembi® (lecanemab-irmb) för…
|
Swedish | 194.3 KB | ||
| 2025-01-27 00:30 |
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatme…
|
English | 188.4 KB | ||
| 2024-12-19 07:30 |
BioArctic announces global license agreement with Bristol Myers Squibb for BioA…
|
English | 211.9 KB | ||
| 2024-12-19 07:30 |
BioArctic och Bristol Myers Squibb ingår globalt licensavtal för BioArctics pyr…
|
Swedish | 204.8 KB | ||
| 2024-11-29 18:30 |
Antal aktier och röster i BioArctic AB (publ) per den 29 november 2024
|
Swedish | 138.8 KB | ||
| 2024-11-29 18:30 |
Number of shares and votes in BioArctic AB (publ) as of November 29, 2024
|
English | 139.2 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
